Stereotactic Radiosurgery
RadiationStereotactic Radiosurgery (SRS) to the index lesion will be delivered with standard of care technique at doses of 18Gy or 21Gy, for tumors >3cm and ≤3cm, respectively, in a single fraction.
NCT Number: NCT07802353
The researchers are doing this study to see if treating people's brain tumors with stereotactic radiosurgery (SRS) before tumor resection surgery will prevent cancer cells from spreading to other areas of the brain, including the fluid and lining around the brain, during surgery, and lead to better surgical outcomes and fewer complications after surgery (post-surgery complications). Only one brain tumor (the index tumor) will be treated with the study radiosurgery and then removed by surgery. If there are other brain tumors, they will not be removed by surgery in this study, although they may be treated separately with standard radiation if the doctor decides it is needed.
Interested in participating?
Request Info18 year and older
All sexes
Interventional
Phase 2
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Stereotactic Radiosurgery (SRS) to the index lesion will be delivered with standard of care technique at doses of 18Gy or 21Gy, for tumors >3cm and ≤3cm, respectively, in a single fraction.
Patients will undergo standard-of-care surgical resection of the index lesion within 10 days of SRS, and no later than 21 days to accommodate operating room availability.
Time frame: 1 year
to a composite adverse endpoint that includes This endpoint will be measured from date of receipt of SRS. These events are combined because they represent the totality of clinically meaningful central nervous system failure after resection and adjuvant radiation, are competing and partly related processes, and individually occur too infrequently to power a single-arm study.
Contact information is provided by the study sponsor or research team.
Memorial Sloan Kettering Cancer Center
Other
PReoperative Dose Escalated Stereotactic radioSurgery for Resectable Brain Metastases (PRESS)
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06545682
Brain Metastasases, Breast Cancer
Houston, Texas, United States
View Trial DetailsNCT07476781
Brain Metastasases, Central Nervous System
Toronto, Ontario, Canada
View Trial DetailsNCT07717827
Brain (Nervous System) Cancers, Brain Connectivity
Palermo, PA, Italy
View Trial DetailsNCT06888817
Brain Diseases, Brain Metastasases
Amsterdam, Netherlands
View Trial Details